Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Price Target at $46.83

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given a consensus recommendation of “Buy” by the nine research firms that are currently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $46.83.

A number of research firms have issued reports on DNTH. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Oppenheimer increased their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th.

Dianthus Therapeutics Price Performance

DNTH stock opened at $23.34 on Friday. Dianthus Therapeutics has a 52-week low of $18.34 and a 52-week high of $33.77. The company has a 50-day moving average of $22.89 and a two-hundred day moving average of $25.54. The stock has a market capitalization of $690.86 million, a price-to-earnings ratio of -9.34 and a beta of 1.72.

Institutional Trading of Dianthus Therapeutics

Hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth approximately $556,000. Barclays PLC increased its holdings in shares of Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after buying an additional 33,185 shares in the last quarter. HighVista Strategies LLC acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth approximately $542,000. State Street Corp increased its holdings in shares of Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after buying an additional 413,425 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after buying an additional 97,362 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.